NCT04828564View on ClinicalTrials.gov

Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

December 31, 2021

Conditions
SARS-CoV2COVID-19
Interventions
DRUG

Ribavirin Capsules

Ribavirin 200 mg capsules

DRUG

Favipiravir

Favipiravir 200 mg tablets

Trial Locations (4)

34010

Koc University Hospital, Istanbul

34764

Umraniye Training and Research Hospital, Istanbul

06590

Ankara University, School of Medicine, Ankara

06800

Ankara City Hospital, Ankara

Sponsors

Collaborators (1)

Monitor CRO
All Listed Sponsors
collaborator

Ankara City Hospital Bilkent

OTHER

collaborator

Istanbul Umraniye Training and Research Hospital

UNKNOWN

collaborator

Koç University

OTHER

collaborator

Monitor CRO

INDUSTRY

lead

The Scientific and Technological Research Council of Turkey

OTHER

NCT04828564 - Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 | Biotech Hunter | Biotech Hunter